Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22775723 | 1.00 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1ALDH1A1DPP4 | |
| SCHEMBL5692348 | 1.00 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1ALDH1A1DPP4 | |
| Hydrochloric Acid SCHEMBL6774341 | 0.98 | ALDH1A1 (0.47) | SLC1A3SLC1A2SLC1A1ALDH1A1DPP4 | |
| Hydrochloric Acid SCHEMBL3995222 | 0.98 | ALDH1A1 (0.47) | SLC1A3SLC1A2SLC1A1ALDH1A1DPP4 | |
| SCHEMBL28683018 | 0.86 | CYP1A2 (0.48) | SLC1A3SLC1A2SLC1A1ALDH1A1DPP4 | |
| Hydrochloric Acid SCHEMBL3498689 | 0.84 | LTA4H (0.51) | SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3498681 | 0.84 | LTA4H (0.51) | SLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL9098851 | 0.84 | HDAC1 (0.57) | ALDH1A1MMEMEN1KMT2A | |
| SCHEMBL9098856 | 0.84 | HDAC1 (0.57) | ALDH1A1MMEMEN1KMT2A | |
| SCHEMBL8491458 | 0.84 | HDAC1 (0.57) | ALDH1A1MMEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024178360-A2 | AURISTATIN ANALOGS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| CN-1735592-A | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | CN | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| EP-0427463-B1 | Substituted N-(imidazolyl)alkyl alanine derivatives | SMITHKLINE BEECHAM CORP (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5248689-A | Hypotensive agents, congestive heart failure, renal failure or glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-28 | — | — | US | disclosed |
| CN-1051555-A | N-(imidazolyl) the alkyl alanine derivatives that replaces | SMITHKLINE BEECHAM CORP (US) | 1991-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | SLC1A3 256/4885SLC1A2 62/4885SLC1A1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.